OakChart

NeuroPace Inc

NPCEHealthcare·Medical Devices·USA·Small·NASD·Nov 11 • 3:03 PM ET

12.53-0.16 (-1.26%)
2026-11-11 21:03 CET
Market cap
435.58 USD m
Revenue, TTM
98.84 USD m
Net income, TTM
-19.11 USD m
Free cash flow, TTM
-11.61 USD m
EPS diluted, TTM
-0.57
P/E
-
Compare

Price

NPCE against its 20, 50 and 200-day averages
2050200beatearnings
12.0014.0016.0018.0020.00389K779KMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NPCEclose 12.5320-day 12.8150-day 13.41200-day 14.8212.5352w high52w low

36.1% under the 52-week high of 19.60 on 8 May 2026. 52-week low 12.00 on 3 Nov 2026. Last 15 sessions, 16.2% high to low

Volume 0.49× normal · the line is the 50-bar volume average

Profile

NPCE
52-week range, 7% of the way up
12.0019.60

NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components, which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's RNS System is designed for the treatment of medically refractory partial epilepsy and includes implantable and external products. The company was founded by Rebecca L. Kuhn, Frank M. Fischer on November 19, 1997 and is headquartered in Mountain View, CA.

IndexRUT
Employees209
IPOApr 22, 2021
Beta1.93
ATR, 14d0.69
Rel volume0.49
Short float3.20%
Insider own21.91%
Inst own76.66%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap430.07M
Enterprise Value448.30M
Income-19.11M
Sales98.84M
Book/sh0.35
Cash/sh1.51
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees209
IPOApr 22, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S4.35
P/B36.15
P/C8.32
P/FCF-
EV/EBITDA-
EV/Sales4.54
Quick Ratio3.91
Current Ratio4.94
Debt/Eq5.89
LT Debt/Eq5.70
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.57
EPS next Y-0.25
EPS next Q-0.11
EPS this Y16.10%
EPS next Y55.08%
EPS next 5Y53.56%
EPS past 3/5Y30.02% 8.43%
Sales past 3/5Y29.99% 19.44%
EPS Y/Y TTM31.90%
Sales Y/Y TTM11.59%
EPS Q/Q30.93%
Sales Q/Q-2.95%
EarningsNov 12 AMC
EPS/Sales Surpr.17.39% 0.94%

Ownership

Insider Own21.91%
Insider Trans0.00%
Inst Own76.66%
Inst Trans3.09%
ROA-18.82%
ROE-122.05%
ROIC-24.03%
Gross Margin79.63%
Oper. Margin-15.26%
Profit Margin-19.34%
SMA20-2.18%
SMA50-6.59%
SMA200-15.45%
Trades-

Technical

Shs Outstand34.28M
Shs Float26.80M
Short Float3.20%
Short Ratio6.51
Short Interest0.86M
52W High19.60 -36.07%
52W Low12.00 4.42%
Volatility7.02% 5.09%
ATR (14)0.69
RSI (14)45.40
Beta1.93
Rel Volume0.49
Avg Volume131.85K
Volume55,905

Performance

Perf Week-6.07%
Perf Month-1.18%
Perf Quarter-13.65%
Perf Half Y-20.75%
Perf YTD-18.85%
Perf Year-7.12%
Perf 3Y59.62%
Perf 5Y-10.50%
Perf 10Y-
Recom1.00
Target Price19.78
Prev Close12.69
Price12.53
Change %-1.26%

Analyst ratings

latest 10 of 18
DateActionAnalystRating changeTargetImplied
Sep 18, 2026InitiatedKKeyBanc Capital MarketsOverweight$18+43.7%
Jul 23, 2026InitiatedMMizuhoOutperform$22+75.6%
May 28, 2025InitiatedHH.C. WainwrightBuy$18+43.7%
Jan 21, 2025InitiatedUUBSBuy$17+35.7%
Mar 14, 2024UpgradeWWells FargoEqual Weight → Overweight$16 → $20+59.6%
Jan 30, 2024InitiatedLLeerink PartnersOutperform$22+75.6%
Nov 10, 2023InitiatedCCantor FitzgeraldOverweight$11-12.2%
Aug 24, 2023UpgradeMMorgan StanleyUnderweight → Equal-Weight$5 → $6-52.1%
Feb 22, 2023InitiatedLLake StreetBuy$10-20.2%
Apr 06, 2022InitiatedWWolfe ResearchOutperform$13+3.8%

Peers

Mkt cap
TickerCompanyMkt cap
LIVNLivaNova PLC5.02B
MDTMedtronic Plc129.69B
CLPTClearPoint Neuro Inc290.40M
INSPInspire Medical Systems Inc1.78B
ECORElectroCore Inc71.96M
BWAYBrainsway Ltd ADR442.75M
BSXBoston Scientific Corp65.87B
STIMNeuronetics Inc127.86M
NYXHNyxoah SA92.21M
ABTAbbott Laboratories190.36B

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Morrell MarthaCHIEF MEDICAL OFFICERDec 15 '25Sale15.9725,000399,25049,964Mar 04 04:43 PM
MARTHA J MORRELLOfficerDec 15 '25Proposed Sale16.1925,000404,750Dec 15 04:26 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
XHEState Street SPDR S&P Health Care Equipment ETFAUM: 160.14M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B
RSSLGlobal X Russell 2000 ETFAUM: 1.43B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.109--27.138
2026Q22026-08-11-0.180-0.218-0.18022.8322.617
2026Q12026-05-12-0.200-0.230-0.19822.0021.658
2025Q42026-03-03-0.080-0.156-0.08226.5924.758
2025Q32025-11-04-0.110-0.195-0.10627.3524.647
2025Q22025-08-12-0.260-0.223-0.26323.5223.098
2025Q12025-05-13-0.210-0.241-0.20922.5221.887
2024Q42025-03-04-0.180-0.223-0.17621.4721.147
2024Q32024-11-12-0.190-0.269-0.18521.0619.077
2024Q22024-08-13-0.260-0.300-0.26019.2618.307
2024Q12024-05-08-0.320-0.321-0.31618.1217.337
2023Q42024-03-05-0.230-0.315-0.23118.0117.417
2023Q32023-11-06-0.280-0.404-0.27916.4314.235
2023Q22023-08-08-0.360-0.470-0.35816.5112.635
2023Q12023-05-04-0.410-0.458-0.41314.4712.184
2022Q42023-03-02-0.450-0.500-0.44912.7912.405

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.900--1.01941.13-
2021FY-2.170-1.881-1.47645.1844.92
2022FY-1.910-1.968-1.91445.5245.21
2023FY-1.270-1.362-1.27565.4264.48
2024FY-0.930-0.982-0.93279.9179.58
2025FY-0.660-0.765-0.60199.9995.09
2026FY--0.554--100.28
2027FY--0.249--121.95
2028FY--0.066--150.86
2029FY-0.120--188.53
2030FY-0.365--224.56

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2690027.1326.2027.80
2026Q3S2026-10-2391127.1326.2027.80
2026Q3S2026-10-1591127.1326.2027.80
2026Q3S2026-10-12101127.1426.2027.80
2026Q3S2026-10-08101127.1426.2027.80
2026Q3S2026-09-17101127.1426.2027.80
2026Q3S2026-09-16101127.1426.2027.80
2026Q3S2026-09-1191127.0926.2027.80
2026Q3S2026-09-0891127.0926.2027.80
2026Q3S2026-09-0791127.0926.2027.79
2026Q3S2026-08-1491127.0926.2027.79
2026Q3S2026-08-1291127.0626.2027.79
2026Q3S2026-08-1190027.0926.3027.70
2026Q3S2026-07-2890027.0926.3027.70

Estimate history

EPS, annual-1.258-1.019-1.476-1.914-1.275-0.932-0.656-0.5674
Period2019202020212022202320242025TTM
EPS, quarterly-0.26-0.185-0.176-0.209-0.263-0.106-0.082-0.198-0.182
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual36.97241.13845.18345.5265.42179.90699.98698.84
Period2019202020212022202320242025TTM
Sales, quarterly19.25621.0621.46622.52423.5227.35426.58822.06822.826
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual23.82823.82824.45325.04627.82330.14533.57534.283
Period2019202020212022202320242025MRQ
Shares, quarterly29.13929.77830.14532.75133.04433.28133.57533.90934.283
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue98.8499.9979.9165.4245.5245.1841.1436.97
Cost of Goods Sold Incl. D&A20.1422.7720.8217.3013.0311.7510.8710.51
Gross Profit78.7077.2259.0948.1232.4933.4430.2726.46
Selling, General and Administrative Excl. Other93.7893.5680.7675.3073.2957.1743.3248.49
Research and Development27.6927.8923.6520.7821.9518.2115.7018.29
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-15.08-16.34-21.67-27.17-40.79-23.74-13.05-22.03
Interest Expense6.307.468.808.527.537.4111.499.48
Unusual Expense0.120.49-0.300.320.005.24-0.33-1.28
Net Income Before Taxes-19.11-21.46-27.14-32.96-47.08-36.08-24.28-29.97
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-19.11-21.46-27.14-32.96-47.08-36.08-24.28-29.97
Net Income From Continuing Operations-19.11-21.46-27.14-32.96-47.08-36.08-24.28-29.97
Net Income-19.11-21.46-27.14-32.96-47.08-36.08-24.28-29.97
EPS (Recurring)-0.56-0.65-0.94-1.27-1.91-1.33-1.03-1.30
EPS (Basic, Before Extraordinaries)-0.57-0.66-0.93-1.27-1.91-1.48-1.02-1.26
EPS (Diluted)-0.57-0.66-0.93-1.27-1.91-1.48-1.02-1.26
EBITDA-13.03-14.39-19.90-25.57-37.81-23.44-12.74-21.61
Non-Operating Income (Expense)2.392.823.023.051.240.30-0.070.27
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.8411.0910.289.568.354.291.381.44
Price To Sales Ratio5.485.054.084.070.815.46--
Gross Margin79.6377.2373.9473.5671.3874.0073.5971.58
Operating Margin-15.26-16.34-27.12-41.54-89.62-52.54-31.72-59.59
Net Margin-19.34-21.47-33.97-50.38-103.43-79.85-59.02-81.07
Shares Outstanding34.2833.5730.1527.8225.0524.4523.8323.83
Market Capitalization435.58435.58334.00270.9837.11245.09225.15-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue22.8322.0726.5927.3523.5222.5221.4721.06
Cost of Goods Sold Incl. D&A3.924.026.016.195.395.185.285.64
Gross Profit18.9118.0520.5821.1718.1317.3416.1915.42
Selling, General and Administrative Excl. Other24.0523.6222.3423.7724.9622.4919.8419.66
Research and Development6.907.197.036.586.847.446.055.75
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.14-5.57-1.77-2.60-6.82-5.15-3.65-4.24
Interest Expense1.541.521.601.652.062.152.192.18
Unusual Expense0.040.170.00-0.080.490.080.09-0.22
Net Income Before Taxes-6.20-6.69-2.73-3.50-8.65-6.59-5.25-5.45
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-6.20-6.69-2.73-3.50-8.65-6.59-5.25-5.45
Net Income From Continuing Operations-6.20-6.69-2.73-3.50-8.65-6.59-5.25-5.45
Net Income-6.20-6.69-2.73-3.50-8.65-6.59-5.25-5.45
EPS (Recurring)-0.18-0.19-0.08-0.11-0.25-0.21-0.17-0.19
EPS (Basic, Before Extraordinaries)-0.18-0.20-0.08-0.11-0.26-0.21-0.18-0.19
EPS (Diluted)-0.18-0.20-0.08-0.11-0.26-0.21-0.18-0.19
EBITDA-4.61-5.05-1.25-2.11-6.35-4.68-0.57-3.79
Non-Operating Income (Expense)0.520.560.640.670.720.790.680.75
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.302.282.632.633.232.632.602.59
Price To Sales Ratio5.484.455.163.604.134.594.192.68
Gross Margin82.8381.7877.4077.3977.0976.9975.4173.22
Operating Margin-22.53-25.23-6.65-9.51-29.01-22.85-17.02-20.15
Net Margin-27.16-30.31-10.26-12.78-36.78-29.25-24.46-25.89
Shares Outstanding34.2833.9133.5733.2833.0432.7530.1529.78
Market Capitalization435.58442.72514.27341.07365.38400.16334.00203.50

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments61.0652.7666.4577.41115.5838.085.09
Short Term Receivables14.6812.8512.317.487.098.396.02
Inventories16.9013.3811.219.717.826.917.90
Other Current Assets1.442.352.743.112.321.181.25
Total Current Assets94.0781.3492.7297.71132.8254.5620.26
Net Property, Plant & Equipment11.2612.8914.4115.900.600.520.81
Total Investments and Advances0.120.120.120.120.120.370.00
Deferred Tax Assets88.37------
Other Assets0.110.290.400.370.020.510.03
Total Assets193.9494.65107.65114.11133.5655.9521.09
Short Term Debt Incl. Current Port. of LT Debt2.121.861.631.420.002.0462.80
Accounts Payable2.222.952.332.151.380.950.90
Other Current Liabilities13.4810.3412.277.417.926.6011.45
Total Current Liabilities17.8115.1616.2310.989.309.6075.15
Long Term Debt68.7271.4870.7768.3549.8551.190.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities88.37------
Other Liabilities0.000.000.000.000.911.571.73
Total Liabilities174.9086.6387.0079.3360.0662.3676.88
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00141.4273.57
Common Equity19.038.0120.6534.7873.50-147.83-129.35
Total Shareholders Equity19.038.0120.6534.7873.50-6.41-55.78
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity19.038.0120.6534.7873.50-6.41-55.78
Total Liabilities & Stockholders Equity193.9494.65107.65114.11133.5655.9521.09
Book Value Per Share0.570.270.741.393.01-6.20-5.43
Tangible Book Value Per Share0.570.270.741.393.01-6.20-5.43
Full-Time Employees209184171167166152152
Price to Book Ratio36.6133.9216.540.853.352.75-
Return on Assets-14.88-26.83-29.72-38.02-38.08-63.02-
Return on Equity-158.74-189.35-118.91-86.96-107.55--
Return on Invested Capital-24.46-34.14-36.05-45.65-29.25-54.22-
Quick Ratio4.334.485.028.0213.444.970.16
Current Ratio5.285.375.718.9014.285.690.27

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-19.11-21.46-27.14-32.96-47.08-36.08-24.28-29.97
Depreciation2.051.951.771.602.990.300.310.42
Other Funds (Non Cash)10.7412.5212.8814.1312.0110.844.424.52
Funds from Operations-6.32-6.99-12.50-17.22-32.08-24.95-19.54-25.04
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-4.92-4.01-5.45-2.48-4.790.37-2.070.01
Cash from Operating Activities-11.24-11.01-17.95-19.70-36.87-24.58-21.61-25.03
Capital Expenditures-0.37-0.33-0.31-0.17-0.60-0.38-0.06-0.47
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.009.3023.2024.40-85.01-10.714.08
Purchase of Investments0.000.000.000.000.00-85.01-17.00-18.02
Sale Or Maturity of Investments0.000.009.3023.2024.400.006.3022.10
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.37-0.338.9923.0323.80-85.40-10.773.62
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock2.0622.215.218.390.55106.6231.500.04
Repurchase of Common Pref Stock0.00-49.550.000.000.000.000.000.00
Sale of Common Pref Stock2.0671.765.218.390.55106.6231.500.04
Proceedsfrom Stock Options-0.0569.650.00-0.30-0.35105.7031.490.00
Issuance or Reduction of Debt, Net-0.13-2.070.000.000.00-4.0923.5121.33
Change in Long Term Debt-0.13-2.070.000.000.00-4.0910.980.00
Issuance of Long Term Debt-0.1358.440.000.000.000.0053.100.00
Reduction of Long Term Debt0.00-60.510.000.000.00-4.09-42.120.00
Net Financing Active Other Cash Flow-0.52-0.54-0.88-0.26-0.060.000.000.00
Other Financing Activities Uses-0.52-0.54-0.88-0.26-0.060.000.000.00
Cash from Financing Activities1.4119.604.338.130.49102.5355.0121.37
Net Change in Cash-10.208.26-4.6311.45-12.58-7.4522.63-0.04
Free Cash Flow-11.61-11.34-18.25-19.87-37.47-24.96-21.67-25.49
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments51.7053.9861.0660.0162.1466.26
Short Term Receivables14.9314.7914.6814.9413.5515.44
Inventories18.1116.6916.9018.1416.3513.58
Other Current Assets1.451.511.442.241.702.20
Total Current Assets86.1986.9894.0795.3393.7497.48
Net Property, Plant & Equipment10.4610.9611.2611.6812.1612.59
Total Investments and Advances0.240.850.120.120.120.12
Deferred Tax Assets--88.37---
Other Assets0.100.110.110.120.090.01
Total Assets96.9998.90193.94107.25106.11110.20
Short Term Debt Incl. Current Port. of LT Debt2.262.192.122.051.991.92
Accounts Payable4.204.512.224.594.724.05
Other Current Liabilities10.979.4713.4812.9710.448.74
Total Current Liabilities17.4316.1717.8119.6117.1414.71
Long Term Debt67.6768.2868.7269.1369.5371.23
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--88.37---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities85.1184.44174.9088.7486.6885.94
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity11.8814.4519.0318.5219.4424.27
Total Shareholders Equity11.8814.4519.0318.5219.4424.27
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity11.8814.4519.0318.5219.4424.27
Total Liabilities & Stockholders Equity96.9998.90193.94107.25106.11110.20
Book Value Per Share0.350.430.570.560.590.74
Tangible Book Value Per Share0.350.430.570.560.590.74
Full-Time Employees--209---
Price to Book Ratio36.6123.2027.7517.5315.0346.24
Return on Assets-18.82-20.63-14.88-23.57-25.88-23.73
Return on Equity-122.05-111.38-158.74-169.27-176.94-128.49
Return on Invested Capital-7.79-8.09-3.11-3.99-9.72-6.90
Quick Ratio3.914.354.333.944.515.70
Current Ratio4.945.385.284.865.476.63

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-6.20-6.69-2.73-3.50-8.65-6.59
Depreciation0.530.510.520.490.480.46
Other Funds (Non Cash)2.562.662.782.744.003.02
Funds from Operations-3.11-3.510.57-0.27-4.18-3.11
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.80-2.39-0.06-1.672.09-4.37
Cash from Operating Activities-3.90-5.900.51-1.94-2.09-7.48
Capital Expenditures-0.12-0.12-0.10-0.03-0.17-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.12-0.12-0.10-0.03-0.17-0.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.380.010.72-0.050.2021.34
Repurchase of Common Pref Stock0.000.000.000.000.00-49.55
Sale of Common Pref Stock1.380.010.72-0.050.2070.88
Proceedsfrom Stock Options0.000.000.00-0.05-0.5670.27
Issuance or Reduction of Debt, Net0.000.000.00-0.13-1.940.00
Change in Long Term Debt0.000.000.00-0.13-1.940.00
Issuance of Long Term Debt0.000.000.00-0.1358.570.00
Reduction of Long Term Debt0.000.000.000.00-60.510.00
Net Financing Active Other Cash Flow-0.20-0.18-0.09-0.05-0.17-0.23
Other Financing Activities Uses-0.20-0.18-0.09-0.05-0.17-0.23
Cash from Financing Activities1.18-0.170.64-0.23-1.9121.11
Net Change in Cash-2.85-6.181.04-2.21-4.1613.59
Free Cash Flow-4.03-6.020.41-1.97-2.25-7.52

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 79.91M 2025: 99.99M
United States2024: 79.91M 2025: 99.99M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-303.20%0.9M26.8M147.70K
2026-10-153.31%0.9M26.8M164.31K
2026-09-303.37%0.9M26.8M172.26K
2026-09-153.57%1.0M26.8M185.56K
2026-08-313.39%0.9M26.9M189.10K
2026-08-143.14%0.8M26.9M189.84K
2026-07-313.15%0.8M26.1M193.99K
2026-07-153.35%0.9M26.1M185.58K
2026-06-303.44%0.9M26.1M184.95K
2026-06-152.35%0.6M26.1M184.29K
2026-05-292.23%0.6M26.1M210.53K
2026-05-152.35%0.6M26.1M211.43K
2026-04-303.01%0.8M25.7M193.58K
2026-04-153.60%0.9M25.5M189.80K
2026-03-313.74%0.9M25.3M225.30K
2026-03-133.71%0.9M25.3M216.80K
2026-02-273.18%0.8M25.3M205.63K
2026-02-133.47%0.9M25.1M222.91K
2026-01-303.19%0.8M24.9M250.36K
2026-01-153.60%0.9M24.9M245.14K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.509.2012.500.0025.3060.000.000.990-0.0160.001
call5.006.009.300.007.8310.000.000.943-0.0650.002
call7.503.007.500.007.8870.000.000.903-0.0600.003
call10.002.403.900.003.5110.000.000.832-0.0490.005
call12.500.451.905.582.4423.000.000.574-0.1010.008
call15.000.002.000.253.5561120.000.478-0.1550.008
call17.500.002.002.504.3083.000.000.434-0.1860.008
call20.000.001.200.053.4291300.000.286-0.1300.007
call22.500.002.001.503.8652.000.000.265-0.1420.007
call25.000.002.002.264.2584.000.000.251-0.1520.006
call30.000.002.000.004.8800.000.000.232-0.1660.006
call35.000.002.000.005.3750.000.000.219-0.1780.006
put2.500.000.050.005.4630.000.00-0.010-0.0160.001
put5.000.000.050.005.0290.000.00-0.058-0.0650.002
put7.500.001.950.003.1860.000.00-0.094-0.0590.003
put10.000.000.350.101.7302.004.00-0.170-0.0480.005
put12.500.751.701.222.2101.0010.00-0.426-0.0990.008
put15.002.553.503.022.4201.0010.00-0.520-0.1530.008
put17.503.707.000.004.4090.000.00-0.566-0.1840.008
put20.006.209.500.005.0790.000.00-0.677-0.1520.007
put22.508.0011.300.004.5230.000.00-0.697-0.1650.007
put25.0010.1014.300.005.6260.000.00-0.711-0.1760.007
put30.0015.6019.500.006.6090.000.00-0.731-0.1920.006
put35.0020.1024.000.006.3740.000.00-0.743-0.2050.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-20SEC
2026-09-04SCHEDULE 13G/ASEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-284Statement of changes in beneficial ownership of securities2026-08-27SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-288-KCurrent report2026-07-28SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-19SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-19SEC
2026-06-224Statement of changes in beneficial ownership of securities2026-06-19SEC
2026-06-088-KCurrent report2026-06-05SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-044Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-284Statement of changes in beneficial ownership of securities2026-05-27SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-194Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-1200399.25K1
2025-110000

Institutional holders

Manager% owned
Polar Capital Holdings Plc9.67%
Soleus Capital Management, L.P.8.54%
First Light Asset Management, LLC8.39%
MORGAN STANLEY7.79%
BlackRock, Inc.7.27%
ORBIMED ADVISORS LLC4.41%
DRIEHAUS CAPITAL MANAGEMENT LLC4.25%
VANGUARD CAPITAL MANAGEMENT LLC3.60%
DEUTSCHE BANK AG\2.73%
ARMISTICE CAPITAL, LLC2.03%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.66%
iShares Russell 2000 ETF2.02%
VANGUARD EXTENDED MARKET INDEX FUND0.85%
Fidelity Small Cap Index Fund0.84%
iShares Russell 2000 Growth ETF0.73%
BlackRock Advantage Small Cap Core Fund0.66%
Fidelity Small Cap Growth Fund0.62%
Driehaus Micro Cap Growth Fund0.51%
VANGUARD RUSSELL 2000 INDEX FUND0.44%
Fidelity Extended Market Index Fund0.36%

OakChart. NPCE. Cached 15 minutes.